Canadian Hospital starts a Clinical Trial to Study the Effects of Dietary Flax Beverage on Memory and Cognition
Photo by Evelyn Liow
The St. Boniface Hospital is conducting the Clinical Trial to Study the Effects of Dietary Flax Beverage on Memory and Cognition.
The aim of stdy is to investigate the effects of flax beverage consumption on memory and cognition in subjects with memory deficit (i.e., amnestic MCI). In addition, it will correlate PET scan results (for a limited number of participants) and blood biomarker data with memory test results.
It is planned to include 60 participants.
Actual study start date is October 9, 2020. The researchers expect to complete the study by February 28, 2023.
Cognitive/Memory score for CANTAB test is the primary outcome measure.
The study population includes the participants:
- Normal thyroid function (as determined by case history).
- Patients must have MCI or Minor Neurocognitive Disorder according to DSM-5 (see definition of DSM-5 under List of Abbreviations on Page 5).
- Age 60 to 84
There are disease and conditions which do not allow participations, such as:
- Any diagnosis of Alzheimer's Disease (AD) or Dementia by a physician.
- MoCA Cognitive Test Score outside 19-25 inclusive.
- DASS Test Score: Severe or Extremely Severe Score for any of the 3 measurements (Depression, Anxiety or Stress).
- Allergies to any of the components of the Test Product or Placebo.
- Lactose Intolerance or Allergy to any of the product components.
and others.
The location of the study is as follows (further details can be found here https://ichgcp.net/clinical-trials-registry/NCT04645927) Winnipeg, Canada.
